
patients with pharmacoresistant epilepsies, including but not lim-
ited to those with LGI1 mutations, by identifying new pre- and
postsynaptic targets for modulation of circuit excitability by LGI1.
LGI1-deficient mouse: a tool to
understand the function of LGI1
The LGI1 knockout mouse may help understand the function of
this secreted neuronal protein. While the loss of both LGI1 alleles
by somatic mutations in glioma cell lines was first thought to con-
tribute to malignant brain tumours (Chernova et al. , 1998), our
findings emphasize a role in epileptogenesis. Since we found no
evidence for gliomas in LGI1
/
Nissl-stained brains sections
(n = 8), the germinal loss of LGI1 seems unlikely to be related to
brain tumour genesis. While tumours might conceivably develop in
LGI1
/
mice if they did not die prematurely, there is no evidence
for an elevated rate of malignancy in families with ADLTE
(Brodtkorb et al., 2003).
Recent data have shown that LGI1 shapes neuronal morphology
at multiple levels. It forms part of canonical pathways controlling
axon guidance (Kunapuli et al., 2009), hippocampal neurite out-
growth in vitro (Owuor et al., 2009) and postnatal pruning of
granule cell dendrites and glutamatergic synapses (Zhou et al.,
2009). Possibly developmental actions of LGI1 on dendritic and
synaptic maturation contribute to epileptogenesis. We detected no
major anomalies in cortical lamination in either LGI1
/
or LGI1
+/
mice, but further work is needed to define more subtle morpho-
logical changes.
We consistently observed that recurrent seizures were first
initiated at postnatal day 10 in LGI1
/
mice. This date of
onset was not correlated with the developmental pattern of
LGI1 expression. In the wild-type mouse, the antibody we used
(ab30868; specificity proven, since there was no LGI1 signal in
tissue from knockout mice) detected LGI1 as early as embryonic
day 16, somewhat earlier than previous studies (Furlan et al.,
2006; Ribeiro et al., 2008; Zhou et al., 2009). This onset timing
of seizures, loss of body weight and premature death in LGI1
/
mice mirrors that in SCN1A knockout and knock-in mice, which
are models for severe myoclonic epilepsy of infancy (Yu et al.,
2006; Ogiwara et al., 2007). Many significant developmental
events occur in rodents during the restricted time window when
seizures emerge in LGI1
/
mice, including the switch in polarity
of GABAergic signalling in inhibitory interneurons (Ben-Ari and
Holmes, 2006) and the maturation of excitatory synapses termi-
nating on principal cells of the cortex and hippocampus (Zhou
et al., 2009).
Recent reports converge to show that LGI1 regulates the devel-
opment of glutamatergic synapses (Fukata et al., 2010; Yu et al.,
2010) and yet contradict each other. Yu et al. (2010) suggest that
an absence of LGI1 enhances excitatory synaptic transmission with
an increased frequency of excitatory postsynaptic synaptic currents
but no difference in their amplitude (Yu et al., 2010). In contrast,
Fukata and colleagues (2010) found a reduction in the amplitude
of excitatory postsynaptic synaptic currents (selectively of
AMPA-mediated excitatory postsynaptic synaptic currents), but
no change in their frequency (Fukata et al., 2010). Further studies
may reveal the reasons for this difference.
It remains unclear how mutations in or inactivation of LGI1 led
to epilepsy. Possibly, temporally restricted deletion of LGI1 using
inducible Cre transgenic mice may permit the differentiation of
defects in synaptic transmission and/or cellular excitability due to
prenatal or postnatal neuronal development, and those due to a
lack of LGI1 in the adult. LGI1 is a novel type of epilepsy gene,
structurally distinct from ion channel genes involved in other in-
herited epilepsies. The human ADLTE syndrome may therefore
depend on a pathway to enhanced brain excitability different
from those resulting from altered ion channels.
Acknowledgements
The mouse mutant line was established at the Mouse Clinical
Institute—Institut Clinique de la Souris (Illkirch, France). We
would like to thank Jerome Garrigue for genotyping, Annick
Prigent for immunohistochemistry, Philippe Couarch for technical
help and Isabelle Gourfinkel-An and Ste
´
phanie Millecamps for
helpful discussion. We are also grateful to Revital Rattenbach for
kindly providing the PGK-Cre mouse line and Richard Palmiter for
offering the anti-ZnT3 antibody.
Funding
Fondation pour la Recherche sur le Cerveau (FRC); FP6 Integrated
Project EPICURE; Sanofi-Aventis; Japan Society of the Promotion
of Sciences (to S.B.); Ile de France (to E.C.); Contrat d’interface
INSERM (to V.N.) and Agence Nationale de la Recherche
(ANR-08-MNP-013 to C.D.). Funding to pay the Open Access
publication charges for this article was provided by Fondation
pour la Rechercher Medicale.
Supplementary material
Supplementary material is available at Brain online.
References
Baulac S, Baulac M. Advances on the genetics of mendelian idiopathic
epilepsies. Neurol Clin 2009; 27: 1041–61.
Ben-Ari Y, Holmes GL. Effects of seizures on developmental processes in
the immature brain. Lancet Neurol 2006; 5: 1055–63.
Brodtkorb E, Nakken KO, Steinlein OK. No evidence for a seriously
increased malignancy risk in LGI1-caused epilepsy. Epilepsy Res
2003; 56: 205–8.
Chabrol E, Popescu C, Gourfinkel-An I, Trouillard O, Depienne C,
Senechal K, et al. Two novel epilepsy-linked mutations leading to a
loss of function of LGI1. Arch Neurol 2007; 64: 217–22.
Chernova OB, Somerville RP, Cowell JK. A novel gene, LGI1, from
10q24 is rearranged and downregulated in malignant brain tumors.
Oncogene 1998; 17: 2873–81.
de Bellescize J, Boutry N, Chabrol E, Andre-Obadia N, Arzimanoglou A,
Leguern E, et al. A novel three base-pair LGI1 deletion leading to loss
of function in a family with autosomal dominant lateral temporal
epilepsy and migraine-like episodes. Epilepsy Res 2009; 85: 118–22.
LGI1 knockout mice Brain 2010: 133; 2749–2762 | 2761
by guest on May 15, 2015Downloaded from
Kommentare zu diesen Handbüchern